http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20200092864-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_050fc7b82c5d17d9aeb63a7cdcc546b3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_465b607edb4c88aeefb4958e154efaec |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate | 2019-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0699259097bf6575495a1b7d0e55dd8f |
| publicationDate | 2020-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20200092864-A |
| titleOfInvention | IL6 single nucleotide polymorphism marker in gene for predicting risk of drug induced leukopenia and method for predicting risk of drug induced leukopenia using the same |
| abstract | The present invention relates to a composition for predicting the risk of leukopenia including a monobasic polymorphic marker in the IL6 gene and a method for predicting the risk of leukopenia using the same. The monobasic polymorphic marker in the IL6 gene according to the present invention has a high correlation with the risk of leukopenia induced by drugs, in particular, chipurin-based drugs, and thus, leukemia, Crohn's disease, ulcerative colitis, or Customized patient who can effectively predict or diagnose patients with high susceptibility to leukopenia occurring during chemopurine-based drug treatment in organ transplantation, etc., and achieve optimal treatment effects by administering the appropriate drugs to patients. Treatment can be performed efficiently. Furthermore, the monobasic polymorphic marker according to the present invention can be used in drug development studies for the treatment of drug-induced leukopenia. |
| priorityDate | 2019-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 82.